[Federal Register Volume 75, Number 166 (Friday, August 27, 2010)]
[Notices]
[Pages 52751-52752]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-21351]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Office of Global Health Affairs; Trans-Atlantic Task Force on 
Antimicrobial Resistance (TATFAR)

AGENCY: Office of Global Health Affairs, HHS.

ACTION: Notice of public meeting and request for comments.

-----------------------------------------------------------------------

SUMMARY: The Office of Global Health Affairs is seeking comments and

[[Page 52752]]

suggestions from the public on the activities of the Trans-Atlantic 
Taskforce on Antimicrobial Resistance (TATFAR).

DATES: A public meeting will be held in Bethesda, MD, on Friday, 
October 1, 2010 from 1:30 to approximately 4:30 p.m. Persons wishing to 
participate, including those who wish to make an oral presentation, 
must register in advance and provide a copy of their presentation by 
noon Friday, September 24, 2010.
    Deadline for Registration for all Attendees: All Other Attendees 
must register by noon, Friday, September 24, 2010.
    Deadline for Requests for Special Accommodation: Requests for 
special accommodation should be submitted by noon, Friday, September 
17, 2010.

ADDRESSES: Meeting Location: The public meeting will be held on the 
Campus of the National Institutes of Health, 9000 Rockville Pike, 
Building 31, Wing C, Room 6, Bethesda, MD 20892.
    Submission of Written Comments: Written comments can be e-mailed to 
[email protected] or sent via regular mail to Elana Clarke, Office of 
Global Health Affairs, Switzer Building Room 2319, 330 C Street, SW., 
Washington, DC 20201.
    Registration and Special Accommodations: Individuals wishing to 
participate or who need special accommodations or both must register by 
contacting Elana Clarke at [email protected]. See Registration To 
Attend and/or Participate in the Public Hearing for instructions on how 
to submit electronic notices of participation.

FOR FURTHER INFORMATION CONTACT: Elana Clarke at [email protected] 
or 202 260-0443.
    Registration To Attend and/or Participate in the Public Meeting: To 
ensure there is sufficient room we ask that you pre-register. If you 
wish to make an oral presentation during the open public comment period 
of the hearing, state your intention to present on your registration 
submission. To register, please send an electronic mail message to 
[email protected] by the deadline listed under DATES. Your e-mail 
should include your name and e-mail address.
    Please submit a written statement at the time of registration, 
identifying each focus area you wish to address and the approximate 
time requested to make your presentation. Organizations should provide 
this information as well as the names and e-mail addresses of all 
participants. Registered individuals will be notified of the 
approximate time scheduled for their presentation prior to the meeting. 
Depending on the number of presentations, HHS may need to limit the 
time allotted for presentations.

SUPPLEMENTARY INFORMATION: 

1. Background

    On November 3, 2009, the United States and the European Union (EU) 
agreed to establish a task force to focus ``on urgent antimicrobial 
resistance issues focused on appropriate therapeutic use of 
antimicrobial drugs in the medical and veterinary communities, 
prevention of both healthcare- and community-associated drug-resistant 
infections, and strategies for improving the pipeline of new 
antimicrobial drugs, which could be better addressed by intensified 
cooperation.'' (2009 EU-U.S. Summit Declaration).
    The TATFAR is made up of government representatives from the U.S. 
Department of Health and Human Services for the United States and from 
the European Commission, European Union agencies, and representatives 
of three EU member states for the EU. Information about the TATFAR is 
available at: http://ecdc.europa.eu/en/activities/diseaseprogrammes/TATFAR/Pages/index.aspx.

2. Public Comment and Meeting

    The public meeting process provides an opportunity for the public 
to become aware of the activities of the TATFAR to date. In addition, 
OGHA invites written comments and/or oral presentations of interested 
persons on the three focus areas of the TATFAR as defined in the 2009 
EU/US Summit Declaration:
     Appropriate therapeutic use of antimicrobial drugs in the 
medical and veterinary communities,
     Prevention of both healthcare- and community-associated 
drug-resistant infections, and
     Strategies for improving the pipeline of new antimicrobial 
drugs.
    Comments should identify specific antimicrobial resistance-related 
activities in these three areas where intensified cooperation between 
the United States and the European Union could have the most impact, 
keeping in mind that the work of the TATFAR will be carried out using 
currently available resources. In particular, input is sought on 
activities that can be undertaken in the near-term, with a reasonable 
possibility of completion over the next 12-15 months.
    Written comments submitted by e-mail should use the following 
subject line ``TATFAR Comments.'' Comments and any documentation may be 
submitted as Adobe PDF, MSWord or Text (.txt) files. Written comments 
submitted by regular mail should clearly identify ``TATFAR Comments'' 
as the subject.

3. Building and Security Guidelines

    The meeting is being held in a Federal government building; 
therefore, Federal security measures are applicable. In planning your 
arrival time, please take account of the need to clear security. All 
visitors must enter through the NIH Gateway Center and must present 
government-issued photo identification. All persons entering the 
building must pass through a metal detector. All items brought to HHS 
are subject to inspection. For more information on NIH security 
requirements for visitors, please go to: http://www.nih.gov/about/visitorsecurity.htm.

    Signed: August 23, 2010.
Nils Daulaire,
Director, Office of Global Health Affairs.
[FR Doc. 2010-21351 Filed 8-26-10; 8:45 am]
BILLING CODE 4150-38-P